FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Lilly and Novo.
Information in Investors Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. … [+1064 chars]
Discussion (0)
No comments yet. Be the first to share your thoughts!
Join the Conversation
You need to be logged in to leave a comment.
Sign In Create Account